Your browser doesn't support javascript.
loading
Feasibility, effectiveness and cost of a decentralized HCV care model among the general population in Delhi, India.
Markby, Jessica; Gupta, Ekta; Soni, Divya; Sarin, Sanjay; Murya, Mugil; Katapur, Preetishirin; Tewatia, Navneet; Ramachandran, Babu Entoor; Ruiz, Ryan Jose; Gaeddert, Mary; Tyshkovskiy, Alexander; Adee, Madeline; Chhatwal, Jagpreet; Miglani, Sundeep; Easterbrook, Philippa; Sarin, Shiv K; Shilton, Sonjelle.
Afiliação
  • Markby J; FIND, Geneva, Switzerland.
  • Gupta E; The Institute of Liver and Biliary Sciences, New Delhi, India.
  • Soni D; FIND, New Delhi, India.
  • Sarin S; FIND, New Delhi, India.
  • Murya M; FIND, New Delhi, India.
  • Katapur P; FIND, New Delhi, India.
  • Tewatia N; FIND, New Delhi, India.
  • Ramachandran BE; FIND, New Delhi, India.
  • Ruiz RJ; FIND, Geneva, Switzerland.
  • Gaeddert M; Division of Infectious Disease and Tropical Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • Tyshkovskiy A; Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia.
  • Adee M; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Chhatwal J; Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Miglani S; Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Easterbrook P; Directorate General of Health Services, Government NCT of Delhi, New Delhi, India.
  • Sarin SK; Department of Global HIV, Hepatitis and STI Programmes Geneva, World Health Organization, Geneva, Switzerland.
  • Shilton S; The Institute of Liver and Biliary Sciences, New Delhi, India.
Liver Int ; 42(3): 532-540, 2022 03.
Article em En | MEDLINE | ID: mdl-34817928
BACKGROUND AND AIMS: India has a significant burden of hepatitis C virus (HCV) infection and has committed to achieving national elimination by 2030. This will require a substantial scale-up in testing and treatment. The "HEAD-Start Project Delhi" aimed to enhance HCV diagnosis and treatment pathways among the general population. METHODS: A prospective study was conducted at 5 district hospitals (Arm 1: one-stop shop), 15 polyclinics (Arm 2: referral for viral load (VL) testing and treatment) and 62 screening camps (Arm 3: referral for treatment). HCV prevalence, retention in the HCV care cascade, and turn-around time were measured. RESULTS: Between January and September 2019, 37 425 participants were screened for HCV. The median (IQR) age of participants was 35 (26-48) years, with 50.4% male and 49.6% female. A significantly higher proportion of participants in Arm 1 (93.7%) and Arm 3 (90.3%) received a VL test compared with Arm 2 (52.5%, P < .001). Of those confirmed positive, treatment was initiated at significantly higher rates for participants in both Arms 1 (85.6%) and 2 (73.7%) compared to Arm 3 (41.8%, P < .001). Arm 1 was found to be a cost-saving strategy compared to Arm 2, Arm 3, and no action. CONCLUSIONS: Delivery of all services at a single site (district hospitals) resulted in a higher yield of HCV seropositive cases and retention compared with sites where participants were referred elsewhere for VL testing and/or treatment. The highest level of retention in the care cascade was also associated with the shortest turn-around times.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepacivirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Hepacivirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article